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docetaxel on three oestrogen receptor-negative cancer
cell lines is mediated by the induction of apoptosis
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Summary The taxanes are a promising family of anti-tumour drugs that block cell cycle replication by interfering with the microtubule
network. The clinical use of these drugs involves some problems related to their low solubility and occurrence of resistance, which is mainly
dependent on the multidrug-resistant (MDR) phenotype. To investigate the possible interaction between docetaxel and tamoxifen (TAM),
three oestrogen receptor-negative cancer cell lines, MDR- MDA-MB 231, MDR + CEM-VBLr and MCF-7 ADRr, were used. In all three cell
lines, the combination of docetaxel and TAM was more effective in terms of growth inhibition than single drug exposure. Isobolic analysis
confirmed the presence of synergism in all cell lines when docetaxel was used at 0.2gM and TAM at a dose equal to or higherthan 1 gM. Flow
cytometric DNA analysis performed on the three cell lines showed that TAM was able to increase the G/M blocking activity of docetaxel. This
blocking activity was followed by an increased flow cytometric DNA fragmentation suggestive of the presence of apoptosis, which was
confirmed by DNA gel fragmentation and morphological analysis. While an antagonistic effect on P-glycoprotein (P-gp) activity may contribute
to the synergistic effect of tamoxifen and docetaxel on CEM-VBLr and MCF-7 ADRr, other mechanisms must be involved, as the synergistic
effect is also apparent with a P-gp-negative cell line.
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The taxanes are a new class ofcytotoxic agents thecellulartargetof
which is the microtubule network. Their mechanism of action is
considered to be the enhancement of tubuline polymerization in
both the initiation and elongation of microtubules (Schiff et al,
1979). In this way, taxanes induce extensive formation of micro-
tubule bundles, thereby blocking cell replication at a checkpoint
between G2 and M phase of the cell cycle. Paclitaxel (formerly
called taxol) and docetaxel (formerly called taxotere) were the first
members of the taxane family to be developed and have been
approved by the US Food and Drug Administration for the treat-
ment of ovarian and breast cancer respectively. Phase II trials are
now in progress to extend their application to a wide variety of
carcinomas, including lung, colon, head and neck, prostate, cervical
and brain cancer (Mastropaolo et al, 1995). However, despite this
encouraging therapeutic potential, the clinical use of these drugs
involved some problems related to the solubility, toxicity and
development of drug resistance, the last-named mainly dependent
on an increased MDR activity (Bhalla et al, 1994). In an attempt to
minimize these problems, two complementary strategies can be
employed: paclitaxel and docetaxel analogues with a better thera-
peutic efficacy and less toxicity can be developed and possible
synergism with other chemotherapeutics can be investigated.
The aim of this study was to test the in vitro efficacy of
docetaxel in association with the anti-oestrogen tamoxifen (TAM).
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This combination was chosen on the basis ofprevious reports indi-
cating that TAM can mediate a synergistic effect with cisplatin
(McClay et al, 1989; Scambia et al, 1992), doxorubicin (Leonessa
et al, 1994) and vinblastine (Trump et al, 1992) in oestrogen
receptor (ER)-negative cell lines. Our results showed that this
synergism occurred in the ER-negative MCF-7 ADRr, CEM-
VBLr and MDA-MB 231 cell lines, since a consistent increase in
docetaxel activity was found in association with TAM, thereby
suggesting a possible new approach for improving the therapeutic
validity ofthe taxane family ofanti-tumour drugs.
MATERIALS AND METHODS
Drugs
Docetaxel and paclitaxel were solubilized in dimethyl sulphoxide
(DMSO; stock solution 10 mM) and used within 7 days. Similarly,
newly developed paclitaxel analogues, IDN5102 and IDN5106,
kindly provided by Indena (Milan, Italy) were prepared and used.
The control cells were treated with the same amount of vehicle
alone. TAM stock solutions (100gIM) were in absolute DMSO and
were used at concentrations ranging from 0.1 to 10 JIM. The final
DMSO concentration never exceeded 0.2% (v/v) in either control
or treated samples.
Cell cultures
Two breastcancercell lines (MDA-MB 231 andMCF-7 ADRr) and
one leukaemic cell line (CEM-VBLr) were used. The MDA-MB
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Figure 1 Line charts show the effect of various concentrations of docetaxel alone on MCF-7 ADRr (A), CEM-VBLr (B) and MDA-MB 231 (C) cell lines. Bar
charts represent the growth inhibition effect of docetaxel in combination with increasing doses of TAM on MCF-7 ADRr (D), CEM-VBLr (E) and MDA-MB 231
(F) cell lines. Each point is the mean of the three separate experiments performed in triplicate. Standard deviations were less than 10% and have been omitted
231 cell line was purchased from the American Type Culture
Collection (Rockville, MD, USA); the multidrug-resistant (MDR)
MCF-7 ADRr line, selected for doxorubicin (DOX) resistance as
described previously (Scambia et al, 1994), was kindly provided
by Dr Kenneth H Cowan (National Cancer Institute, NIH,
Bethesda, MD, USA). MDA-MB 231 cells were grown in
minimum essential medium (MEM) and MCF-7 ADRr cells in
RPMI-1640 medium supplemented with 10 tM DOX. The media
were complemented with 10% fetal calf serum (FCS) and 200 U
ml-' penicillin (Sigma, St Louis, MO, USA). Cells, propagated
as monolayer cultures in 75-cm2 tissue culture flasks, were
trypsinized weekly and plated at a density of 8 x 104 cells per ml.
The CEM-VBLr cell line was grown in RPMI-1640 medium
supplemented with 10% FCS, 200 U ml' penicillin and 100 ng
ml' vinblastine (VBL). Cells were seeded at 2-3 x 105 cells per ml
and split in a ratio of 1:3 every day. All cultures were incubated at
37°C under 5% carbon dioxide: 95% air in ahigh-humidity atmos-
phere. The MCF-7 ADRr and CEM-VBLr cell lines exhibit the
classical MDR phenotype [mdr-1 mRNA and P-glycoprotein
(P-gp) overexpression] and are ER negative (Berman et al, 1991;
Scambia et al, 1991).
Growth experiments
Cells were plated in six-well flat-bottom plates (Falcon, Lincoln
Park, NJ, USA) at a density of 105 cells per ml in complete
medium. After 24 h, the medium was replaced with fresh medium
containing TAM and/ordocetaxel andincubation was continued for
72 h. Control cells were treated with vehicle alone. Quadruplicate
counts oftriplicate cultures were performed after 3 days' exposure
to the drugs.
Evaluation of drug interaction
In synergy experiments, dose-response curves for the single
agents were generated first. The effect of the combined treatment
was analysed by the isobole method (Berenbaum, 1981) for a
combination ofdrugs A andB, applying the equation:AC/Ae +Bc/Be
=D, whereAC andBC correspond to concentrations ofdrugs used in
the combination treatment, and Ae and Be correspond to concentra-
tions of drugs able to produce, alone, the same magnitude of
effect. If D (combination index) < 1, the effect of combination is
synergistic, whereas if D = 1 or D > 1, the effect is additive or
antagonistic respectively (Berenbaum, 1981).
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Cell cycle analysis
Cells were plated in the specific medium supplemented as above.
After 24 h, the medium was replaced with fresh medium
containing the compounds to be tested or vehicle alone. After
various times of culture (from 6 h to 72 h), cells were harvested
and nuclei isolated and stained using a solution containing 0.1%
(m/v) sodium citrate, 0.1% (v/v) NP40, 4 mM EDTA and 50 gg
ml-' propidium iodide (PI) as DNA dye (Ferlini et al, 1996).
Incubation of the cells with the staining solution lasted for a
minimum of 24 h at 4'C. Flow cytometric DNA ploidy analysis
was performed by acquiring a minimum of 20 000 nuclei with an
Epics-XL flow cytometer (Coulter Immunology, Miami, FL,
USA). DNA fluorescence was collected in linear mode and pulse
signal processing was used to set a doublet discrimination gate.
Cell cycle analysis was performed using the Multicyle software
package (Phoenix, San Diego, CA, USA).
Gel analysis of DNA fragmentation
Briefly, 2.5 x 106 cells were lysed with 2 ml oflysis buffer [50 mm
Tris-HCl, pH 8, 100 mM EDTA, 0.5% sodium dodecyl sulphate
(SDS)] and incubated for 2 h at 56°C with 20 ,ug ml-' proteinase K
(Sigma). Since the apoptotic process is responsible for the detach-
ment of dead cells, in the MCF-7 ADRr cell line adherent and
detached cells were used separately. DNA was extracted with
phenol, precipitated with ethanol, resuspended in 100 ,ul of TE
(10 mm Tris-HCl, pH 8, 1 mM EDTA) and incubated for 15 min at
65°C with 20 ,ugml-' RNAase A (Sigma). Aliquots (20 ml) ofeach
sample were electrophoresed on 2% agarose gel for 1 h at 7 V cm-'
and visualized with ethidium bromide staining.
Morphological analysis
Treated and control cells were seeded in eight sterile chamber
slides (Nunc, Naperville, IL, USA) coated with 0.01% (v/v) poly-
L-lysine (Sigma). Poly-L-lysine was used as cell adhesive to mini-
mize the release ofdead cells from the monolayer ofvital adherent
cells. After 24 h of culture, chambers were removed and slides
were stained with May-Grunwald - Giemsa.
RESULTS
Docetaxel and TAM positively interact to achieve
growth inhibition
MDA-MB 231, MCF-7 ADRr and CEM-VBLr were cultured in
the presence of docetaxel alone (range 0.05-10 tM) and TAM
alone (range 0.1-10 tM) to establish the growth inhibition effect of
single drug exposure. Cell count analysis showed that half
maximal growth-inhibitory concentration (IC50) was reached in the
presence ofdocetaxel at 0.8 nm, 700 nm and 580 nm on MDA-MB
231, MCF-7 ADRr and CEM-VBLr cell lines respectively. MDA-
MB 231 cells were particularly sensitive to docetaxel as, in
contrast to the other two cell lines used here, they do not express
the classical MDR phenotype, the major resistance factor for
taxanes (Bhalla et al, 1994). Even if all three cell lines do not
express ER, the single treatment with TAM was also effective in
terms of growth inhibition, with IC50 values of 6.1 gM for MDA-
MB 231, 8 gM for MCF-7 ADRr and 5 jiM for CEM-VBLr.
In order to evaluate the interaction of docetaxel with TAM,
MCF-7 ADRr, CEM-VBLr and MDA-MB 231 cells were cultured
in the presence of increasing doses of TAM (range 0.1-10 ,UtM) in
combination with a concentration of docetaxel able to induce a
growth inhibition of30% (IC30), which is the lowest concentration
required to achieve synergism. Cell count analysis showed that an
appreciable increase in cytotoxic effect was visible in all the
cultures treated with the combination of docetaxel and TAM
(Figure 1). To evaluate the presence of synergism, growth experi-
ments were analysed by the isobole method (Berenbaum, 1981),
which demonstrated a synergistic antiproliferative effect (D<l;
Table 1) in all cell lines when TAM was used at a concentration
equal to or higher than 1 gM.
Taxanes and TAM induce cell cycle block in G2M phase
of the cell cycle and DNA fragmentation in a coordinate
time-dependent manner
Since taxanes induce cell cycle block in G2M phase of the cell
cycle, flow cytometric DNA analysis was performed to evaluate
the presence ofcell cycle perturbation. The MCF-7 ADRr cell line
Table 1 Synergistic antiproliferative activity of tamoxifen and docetaxel
Tamoxifen (gm) Docetaxel (gM) Percentage of Tamoxifen (gM) Docetaxel (gM) D
(AC) (BC) control (A.) (BJ
MCF-7 ADRr 0.1 0.2 76 0.17 0.08 3.09
1 0.2 58 5 0.44 0.47
5 0.2 46 10 1 0.70
10 0.2 29 25 3.1 0.46
CEM VBLr 0.1 0.2 66 0.85 0.29 0.81
1 0.2 50 5.2 0.55 0.55
5 0.2 30 39 0.95 0.34
10 0.2 8 >50 3.8 0.25
MDA-MB 231 0.1 0.00025 90 0.19 0.0001 3.03
1 0.00025 67 2.6 0.00065 0.76
2 0.00025 56 4.3 0.0011 0.69
5 0.00025 39 7.4 0.0024 0.77
Ac and Be, concentrations of drugs used in the combination treatment; Ae and Be, concentrations of drugs able to produce, alone, the same magnitude of effect;
D (combination index) < 1 = synergistic effect; D 2 1 = additive or antagonistic affect.
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Figure 2 Cell cycle analysis of MCF-7 ADRr cells after 24 h (A) and 72 h (B) of culture. In the columns (from left to right), cultures were treated with vehicle
alone (0.2% DMSO) and 10gM TAM. In the rows (from top to bottom), cultures were treated with the vehicle alone (0.2% DMSO), 0.2, 0.5 and 1 gM docetaxel.
A docetaxel dose-dependent G/M block of the cell cycle was visible after 24 h of culture when TAM was used at 10 ,UM. After 72 h of culture, the block gave
way to a consistent increase in DNA fragmentation, visible as a clear distinct hypodiploid peak
Table 2 Cell cycle analysis of MCF-7 ADRr cell line treated with 10gM TAM and docetaxel
24 h 72 h
G, S G2M DNA G, S G2M DNA
fragmentation (%)a fragmentation (%)a
Control 52.4 35 12.7 0.3 53.1 35.4 11.5 1.2
TAM (10 ,UM) 64.9 18.2 16.9 4.4 66 22.9 11.2 6.0
Docetaxel (0.2 gM) 51.1 36.3 12.6 1.6 54.2 34.4 11.4 2.2
Docetaxel (0.5 gM) 50.4 37.2 12.4 1.4 54 32.5 12.7 2.6
Docetaxel (1 gM) 47.5 40.7 11.8 3.8 52.9 35.9 11.2 4.9
Docetaxel (0.2gM) 44.8 22.1 33 23.9 50.5 38.5 11 48.7
+TAM (1OigM)
Docetaxel (0.5 IM) 43.4 33.6 23 47.4 68.8 22.6 8.7 57.7
+ TAM (10 ,UM)
Docetaxel (1 ,UM) 14.5 39.3 46.1 56.8 67.4 21.8 10.4 58.8
+ TAM (10 ,UM)
aDNA fragmentation was calculated as the percentage of events falling in thesub-GO/G1 region and was excluded from cell cycle analysis.
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Figure 3 Cell cycle analysis of MDA-MB 231 cells after 12 h of culture. In
the columns (from left to right), cultures were treated with vehicle alone
(0.2% DMSO) and 5 iM TAM. In the rows (from top to boftom), cultures were
treated with the vehicle alone (0.2% DMSO), 0.1, 0.25 and 0.5 nm docetaxel.
Cell cycle block at G/M phase of the cell cycle and DNA fragmentation are
evident in the culture treated with 5gM TAM alone, indicating that the MDA-
MB 231 cell line is more sensitive to TAM than MCF-7 ADRr (Figure 2). In the
cultures treated with the combination of docetaxel and TAM, the number of
blocked cells and DNA fragmentation increases in a docetaxel dose-
dependent manner, resembling the behaviour of the MCF-7 ADRr cell line
(Figure 2)
was cultured in the presence ofincreasing doses ofdocetaxel (0.2,
0.5 and 1 JIM) and TAM (0.1, 1 and 10 JIM). After24 h, an augmen-
tation ofcells blocked in G2/M phase ofthe cell cycle was noticed
at a TAM concentration of 10 gM in combination with increasing
docetaxel doses (Figure 2A and Table 2); under these same culture
conditions, after 48 h (data not shown) and 72 h (Figure 2B and
Table 2), the cell cycle block disappeared and gave way to an
increase in apoptosis rate, as inferred by measuring the percentage
ofcells in the hypodiploid region (Darzynkiewicz et al, 1992).
The same experiment was also conducted on the P-gp-negative
MDA-MB 231 cell line, in which docetaxel was used at 0.1, 0.25
and 0.5 nm and TAM at 0.1, 1 and 5 JIM. Cell cycle analysis
performed after 12 h (Figure 3 and Table 3) and 24 h (not shown)
confirmed the presence of a cell cycle block in G2/M phase of the
cell cycle, which subsided later with the appearance ofa consistent
peak ofDNA fragmentation.
The cell cycle blocking activity was also investigated in the
CEM-VBLr cell line, using docetaxel, paclitaxel and two of its
Table 3 Cell cycle analysis of MDA-MB 231 cell line treated with 5 gM TAM
and docetaxel
12 h
G, S G2/M DNA
fragmentation (%)a
Control 36.2 43.8 20 1.2
TAM (5 gM) 20.4 52.5 27 2.4
Docetaxel (0.0001 gM) 35.7 41.7 22.6 1.9
Docetaxel (0.00025 gM) 35.8 41.9 22.4 2.3
Docetaxel (0.0005 gM) 33.5 46.7 19.7 3.8
Docetaxel (0.0001 gM) 24.9 49.4 25.7 11.6
+ TAM (5 ,UM)
Docetaxel (0.00025 gM) 10.8 62.6 26.6 23.4
+ TAM (5lM)
Docetaxel (0.0005 ,M) 14.1 57.8 28.1 27.4
+ TAM (5 gM)
aDNA fragmentation was calculated as the percentage of eventsfalling in the
sub-GJG, region and was excluded from cell cycle analysis.
newly developed analogues (IDN5102 and IDN5106) that proved
to be more active in vitro than paclitaxel (Distefano et al, manu-
script in preparation). The whole taxane panel was used at a fixed
IC30, in combination with increasing doses of TAM (0.1, 1 and 10
,UM). Starting from 6 h of culture, all the taxanes exhibited an
increased G2/M blocking activity, particularly evident when TAM
was used at 10 gM (Figure 4A). The disregulation ofthe cell cycle
was much more evident after 24 h of culture (Figure 4B) when,
along with a more consistent G2/M block, DNA fragmentation
increased, further confirming that apoptosis and cell cycle arrest
were strictly and temporally correlated.
Morphological and biochemical features of apoptosis
induced by docetaxel and TAM in CEM-VBLr and MCF-7
ADRr cells
In many cell systems, low molecular weight DNA fragments
produced during apoptotic endonucleolysis are responsible for the
typical 'ladder' pattern in agarose gel electrophoresis (Wyllie,
1980). To confirm further that the combination of docetaxel and
TAM actually induced apoptosis, DNA fragmentation gel elec-
trophoresis was performed in the CEM-VBLr and MCF-7 ADRr
cell lines. A typical 'ladder' pattern was found when the combina-
tion was tested on CEM-VBLr cells, whereas no signs of DNA
'laddering' were evident in the MCF-7 ADRr cell line (Figure 5).
This suggests that apoptosis may also occur in the absence of the
classical low molecular weight DNA fragmentation. In order to
test this hypothesis, classical nuclear changes related to the apop-
totic process - reduction of nuclear size, chromatin condensation,
marginalization and nuclei fragmentation (Ferlini et al, 1996) -
were investigated by morphological analysis (Figure 6). MCF-7
ADRr cells were treated with docetaxel alone and with increasing
doses ofTAM (0.1, 1 and 10 tM). Untreated control cells exhibited
only 12% of cells with condensed and marginalized chromatin.
Treatment with 0.2 gM docetaxel alone increased anisonucleosis
but did not induce consistent changes in chromatin structure.
Treatment with 0.2gM docetaxel in combination with0.1 and 1 gM
TAM increased the number ofcells with condensed and marginal-
ized chromatin (28% and 52% respectively) and only marginally
increased the number ofcells with fragmented nuclei (2% and 4%
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Figure 4 Cell cycle analysis of CEM-VBLr cells after 6 h (A) and 24 h (B) of culture. In the columns (from left to right), cultures were treated with the vehicle
alone (0.2% DMSO), 0.1, 1 and 10 gM TAM. In the rows (from top to bottom), cultures were treated with vehicle alone (0.2% DMSO), 0.2 gM docetaxel, 0.5 gM
paclitaxel, 0.2 gM IDN5102 and 0.5 gM IDN5106. The dose used for all the taxanes was chosen according to the IC30. All taxanes induced cell cycle block and
DNA fragmentation when used in combination with 10 gM TAM in a time coordinate-dependent manner, thereby confirming that cell cycle arrest and apoptosis
are sequentially correlated
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Figure 5 Agarose gel electrophoresis of nuclear DNA of MCF-7 ADRr (A)
and CEM-VBLr (B) cells. Lane 1, weight markers; lane 2, cells treated with
0.1% DMSO; lanes 3-5 cells treated with the combination of 0.2 AM
docetaxel and 0.1 gM TAM (lane 3), 1 gM TAM (lane 4) and 10 gM TAM (lane
5). A typical 'ladder' pattern is visible only for CEM-VBLr cells and not for the
MCF-7 ADRr cell line
respectively). Conversely, the morphological pattem of cultures
treated with 0.2 gM docetaxel and 10 gM TAM showed aconsistent
increase in cells with either fragmented nuclei (45%) orcontaining
apoptotic bodies (27%), thereby confirming the presence of a large
number ofapoptotic cells.
DISCUSSION
The taxanes, a promising class of anti-tumour drugs, are known to
induce cell cycle block in the G2/M phase ofthe cell cycle by inter-
fering with the normal regulation of the microtubule network. In
this paper, we have demonstrated that the anti-oestrogen TAM was,
by a synergistic effect, capable ofenhancing the in vitro activity of
docetaxel on three different cancer cell lines. Since our experi-
mental models were based on cell lines that do not express ER, the
explanation of this synergism cannot be related to the anti-oestro-
genic properties ofTAM (Jordan and Murphy, 1990). Moreover, it
has been reported previously that TAM may induce ER-indepen-
dent apoptosis in human breast cancer cells (Perry et al, 1995).
MCF-7 ADRr and CEM-VBLr are cell lines characterized by the
classical MDR phenotype with overexpression of P-gp activity.
TAM was previously reported to be an MDR phenotype reverting
agent (Ramu etal, 1984), and the taxanes are known tobe a substrate
ofP-gp activity. So, onprinciple, the synergistic effectobservedhere
could be dependent on modulation ofP-gp activity. However, TAM
was previously probed in vitro and in vivo (Hofmann et al, 1988;
McClay et al, 1989; Scambia et al, 1992) as a synergistic agent for
cisplatin, which induces a P-gp-independent resistance. Further-
more, our previous reports showed that, in contrast to other anti-
oestrogens, such as ICI 182, 780, TAM was unable under ourculture
conditions to revert the MDR phenotype classically in terms of
modulation of P-gp protein, MDR-1 mRNA expression or efflux
activity as measuredby rhodamine 123-based assay (De Vincenzo et
al, 1996). Moreover, the combination of docetaxel and TAM was
also effective on MDA-MB 231, indicating-that the synergism also
operates in cell lines that do not express P-gp activity.
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Figure 6 Morphological analysis of MCF-7 ADRr cells cultured in the presence of vehicle alone (0.2% DMSO; A) 0.2 gM docetaxel alone (B), 0.2 gM docetaxel
and 1 gM TAM (C) and 0.2 gM docetaxel plus 10 gM TAM (D). Cells were grown in eight-chamber slides and cultures were interrupted after 24 h and stained with
May-Grunwald-Giemsa. In (A), cells are characterized by a finely granular chromatin texture and several nucleoli. In (B), chromatin texture is similar to (A), but
an increased amount of anisonucleosis is detectable. In (C), there is a consistent decrease in the number of nucleoli and some cells show nuclear shrinkage
and polarization and/or chromatin condensation into crescents along the nuclear envelope (arrows). In (D), in virtually all the cells nucleoli are absent and a
large number of cells show condensed and highly fragmented chromatin and/or apoptotic bodies in the cytoplasm (arrows)
Cell cycle analysis showed that the synergism was associated
with an increased number of cells blocked in G2/M phase of the
cell cycle, indicating that the presence of high levels of TAM
induces cell cycle arrest at concentrations of docetaxel that are
ineffective if used alone. Interestingly, after cell cycle block in the
G2/M phase of the cell cycle, an augmentation of flow cytometric
DNA fragmentation - a hallmark of apoptosis in a number of
experimental models (Darzynkiewicz et al, 1992) - was noticed.
The presence of apoptosis was further confirmed by the classical
DNA 'laddering' in the CEM-VBLr cell line and by morphological
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analysis in MCF-7 ADRr cells. In keeping with previous reports
(Bardon et al, 1987; Warn et al, 1993), in this cell system typical
apoptotic nuclear morphology was found in the absence of the
classical low molecular weight DNA fragmentation, thereby
confirming that 'ladder' pattern DNA is not a mandatory endpoint
ofthe apoptotic process.
An increased blocking activity and induction offlow cytometric
DNA fragmentation was also noticed for paclitaxel and its two
newly developed analogues, prompting us to hypothesize that all
the members of the taxane family share with docetaxel the ability
to interact positively with TAM. Taken together, these findings
indicate that the increased G2/M blocking activity culminates in
the massive induction ofapoptosis and suggest that the chemosen-
sitizing effect of TAM may reflect its ability to facilitate a
docetaxel-induced apoptosis. Some pharmacological properties of
TAM could be responsible for this phenomenon, such as calcium
channel blocking activity (Lopes et al, 1990), inhibition ofprotein
kinase C (Issandou et al, 1990) and production of reactive oxygen
species with consequent downward expression of intracellular
thiols (C Ferlini, unpublished results). Further studies on these
possible mechanisms of action are now in progress in our labora-
tory to clarify whether they are targeted during apoptosis induced
by the combination ofdocetaxel and TAM.
The minimum doses required to obtain synergism in both MDR-
positive cell lines were 1 ,UM TAM and 0.2 gM docetaxel, and these
are clinically important because similar levels can safely be
achieved (Sclichenmyer and Von Hoff, 1991; Trump et al, 1992),
particularly inside the tumour tissue, where TAM levels may
considerably exceed those in the peripheral circulation (Lien et al,
1991). The taxanes are currently used in polychemotherapy proto-
cols, and there may be obvious theoretical advantages in adding
TAM to taxane-containing regimens, since it acts as a synergistic
agent in combination with other important anti-tumour drugs, such
as doxorubicin and cisplatin. Thus, if these results are confirmed
using in vivo models, prospective clinical trials will be essential to
verify whether the addition ofTAM to taxane-containing regimens
is clinically relevant.
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